A combination treatment of low-dose dexamethasone and aspirin-triggered resolvin D1 reduces Sjögren syndrome-like features in a mouse model.
Salivary glands
inflammation
lipid mediators
resolvins
steroids
Journal
JADA foundational science
ISSN: 2772-414X
Titre abrégé: JADA Found Sci
Pays: United States
ID NLM: 9918539088106676
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
ppublish
Résumé
Sjögren syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration and diminished secretory function of the salivary glands. Dexamethasone (DEX) resolves dry mouth and lymphocytic infiltration; however, this treatment is difficult to maintain because of multiple adverse effects (eg, osteoporosis and skin thinning); likewise, aspirin-triggered resolvin D1 (AT-RvD1) increases saliva secretion but cannot eliminate lymphocytic infiltration. Previous studies showed that a combination of low-dose DEX with AT-RvD1 before disease onset prevents SS-like features in a mouse model; however, this is not clinically practical because there are no reliable indicators of SS before disease onset. Therefore, the authors applied the combined treatment at disease onset to show its efficacy and comparative lack of adverse effects, so that it may reasonably be maintained over a patient's lifetime. NOD/ShiLtJ mice were treated with ethanol (vehicle control), high-dose DEX alone, AT-RvD1 alone, or a combination of low-dose DEX with AT-RvD1 at disease onset for 8 weeks. Then saliva flow rates were measured, and submandibular glands were harvested for histologic analyses. A combined treatment of low-dose DEX with AT-RvD1 significantly decreased mast cell degranulation and lymphocytic infiltration, increased saliva secretion, and restored apical aquaporin-5 expression in submandibular glands of NOD/ShiLtJ mice. Low-dose DEX combined with AT-RvD1 reduces the severity of SS-like manifestation and prevents the development of advanced and potentially irreversible damage, all in a form that can reasonably be administered indefinitely without the need to cease treatment because of secondary effects.
Sections du résumé
Background
UNASSIGNED
Sjögren syndrome (SS) is an autoimmune disease characterized by lymphocytic infiltration and diminished secretory function of the salivary glands. Dexamethasone (DEX) resolves dry mouth and lymphocytic infiltration; however, this treatment is difficult to maintain because of multiple adverse effects (eg, osteoporosis and skin thinning); likewise, aspirin-triggered resolvin D1 (AT-RvD1) increases saliva secretion but cannot eliminate lymphocytic infiltration. Previous studies showed that a combination of low-dose DEX with AT-RvD1 before disease onset prevents SS-like features in a mouse model; however, this is not clinically practical because there are no reliable indicators of SS before disease onset. Therefore, the authors applied the combined treatment at disease onset to show its efficacy and comparative lack of adverse effects, so that it may reasonably be maintained over a patient's lifetime.
Methods
UNASSIGNED
NOD/ShiLtJ mice were treated with ethanol (vehicle control), high-dose DEX alone, AT-RvD1 alone, or a combination of low-dose DEX with AT-RvD1 at disease onset for 8 weeks. Then saliva flow rates were measured, and submandibular glands were harvested for histologic analyses.
Results
UNASSIGNED
A combined treatment of low-dose DEX with AT-RvD1 significantly decreased mast cell degranulation and lymphocytic infiltration, increased saliva secretion, and restored apical aquaporin-5 expression in submandibular glands of NOD/ShiLtJ mice.
Conclusions
UNASSIGNED
Low-dose DEX combined with AT-RvD1 reduces the severity of SS-like manifestation and prevents the development of advanced and potentially irreversible damage, all in a form that can reasonably be administered indefinitely without the need to cease treatment because of secondary effects.
Identifiants
pubmed: 37622089
doi: 10.1016/j.jfscie.2022.100016
pmc: PMC10448398
mid: NIHMS1926175
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIDCR NIH HHS
ID : R01 DE027884
Pays : United States
Références
Int J Mol Sci. 2013 Mar 08;14(3):5501-18
pubmed: 23528855
Br J Pharmacol. 2008 Mar;153 Suppl 1:S200-15
pubmed: 17965751
Int J Clin Exp Pathol. 2014 Apr 15;7(5):1988-96
pubmed: 24966908
J Biol Chem. 2007 Mar 30;282(13):9323-9334
pubmed: 17244615
Nature. 2014 Jun 5;510(7503):92-101
pubmed: 24899309
Ann Diagn Pathol. 2022 Feb;56:151865
pubmed: 34847389
Intern Med. 1999 Dec;38(12):938-43
pubmed: 10628930
Eur J Pharmacol. 2016 Aug 15;785:144-155
pubmed: 26546247
J Clin Med. 2020 Jul 20;9(7):
pubmed: 32698400
Health Qual Life Outcomes. 2009 May 27;7:46
pubmed: 19473510
Biochim Biophys Acta. 2008 Mar;1778(3):757-69
pubmed: 18086552
Biochim Biophys Acta. 2006 Aug;1758(8):1061-70
pubmed: 16537077
Mol Aspects Med. 2017 Dec;58:1-11
pubmed: 28263773
Acta Histochem Cytochem. 2012 Oct 31;45(5):251-9
pubmed: 23209334
Inflamm Res. 2016 Aug;65(8):635-45
pubmed: 27056390
Nat Rev Rheumatol. 2021 Jun;17(6):333-348
pubmed: 33911236
Oncogene. 2021 Sep;40(35):5367-5378
pubmed: 34272474
Arthritis Rheum. 2010 May;62(5):1280-9
pubmed: 20131287
J Dent Res. 2014 Mar;93(3):300-5
pubmed: 24389810
Swiss Med Wkly. 2015 Sep 16;145:w14168
pubmed: 26375728
Physiol Rep. 2016 Oct;4(19):
pubmed: 27694530
Med Hypotheses. 2008 Aug;71(2):237-40
pubmed: 18448265
Front Immunol. 2021 Jul 06;12:681941
pubmed: 34295332
Prog Lipid Res. 2022 Apr;86:101165
pubmed: 35508275
FASEB J. 2017 Apr;31(4):1273-1288
pubmed: 28087575
Nat Rev Rheumatol. 2013 Sep;9(9):544-56
pubmed: 23857130
Am J Physiol Cell Physiol. 2014 Jan 15;306(2):C178-85
pubmed: 24259417
Oral Dis. 2017 Jul;23(5):576-597
pubmed: 27426637
Prostaglandins Leukot Essent Fatty Acids. 2008 Sep-Nov;79(3-5):157-63
pubmed: 19008087
J Dent Res. 2016 Jul;95(7):784-92
pubmed: 26933138
Prostaglandins Leukot Essent Fatty Acids. 2017 Feb;117:17-27
pubmed: 28237084
Int J Oral Sci. 2019 Jan 3;11(1):1
pubmed: 30602784
Tissue Barriers. 2016 Mar 10;4(3):e1162348
pubmed: 27583188
Genomics Proteomics Bioinformatics. 2015 Aug;13(4):219-23
pubmed: 26362815
Int J Exp Pathol. 2014 Oct;95(5):351-63
pubmed: 25186305
Autoimmun Rev. 2012 Feb;11(4):252-8
pubmed: 22001522
Expert Rev Proteomics. 2017 Jun;14(6):491-498
pubmed: 28532233
Ann Rheum Dis. 2001 May;60(5):511-3
pubmed: 11302875
PLoS One. 2007 Dec 19;2(12):e1316
pubmed: 18091990
Lab Invest. 2013 Sep;93(9):991-1000
pubmed: 23857007
Rheumatol Int. 2000;19(4):141-7
pubmed: 10836524
Biol Pharm Bull. 2006 Feb;29(2):281-5
pubmed: 16462032
Allergy Asthma Clin Immunol. 2013 Aug 15;9(1):30
pubmed: 23947590
Mucosal Immunol. 2013 Mar;6(2):256-66
pubmed: 22785226
Nat Commun. 2018 Jan 4;9(1):59
pubmed: 29302056
Tissue Eng Part C Methods. 2010 Oct;16(5):1135-44
pubmed: 20121592
Int J Mol Sci. 2020 Jun 16;21(12):
pubmed: 32560266
Ann Rheum Dis. 1990 Sep;49(9):685-9
pubmed: 2241284
Mol Aspects Med. 2017 Dec;58:114-129
pubmed: 28336292
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(9):1670-3
pubmed: 18819897
Mod Rheumatol. 2022 Jul 1;32(4):761-769
pubmed: 34915577
Sci Rep. 2016 Apr 11;6:24244
pubmed: 27064029
BMC Musculoskelet Disord. 2015 Feb 15;16:30
pubmed: 25887888
Am J Pathol. 2018 Jul;188(7):1555-1562
pubmed: 29684359
J Rheum Dis Treat. 2015;1(4):
pubmed: 27110599
Mucosal Immunol. 2016 May;9(3):757-766
pubmed: 26462421
Oxid Med Cell Longev. 2013;2013:185715
pubmed: 24381712
Scand J Immunol. 2020 Mar;91(3):e12852
pubmed: 31733111
J Immunol. 2012 Jul 15;189(2):1036-42
pubmed: 22711890
Ann N Y Acad Sci. 2009 Sep;1173:378-83
pubmed: 19758176
Mediterr J Rheumatol. 2018 Dec 18;29(4):193-198
pubmed: 32185326
Sci Rep. 2017 Mar 31;7:45525
pubmed: 28361884
Scand J Immunol. 2022 Mar;95(3):e13145
pubmed: 35073430
Prostaglandins Other Lipid Mediat. 2017 Nov;133:103-110
pubmed: 28602942
FASEB J. 2016 Aug;30(8):2792-801
pubmed: 27121596
PLoS Biol. 2020 Jul 14;18(7):e3000410
pubmed: 32663219
Crit Care Med. 2015 Dec;43(12):2642-50
pubmed: 26488221
BMC Cancer. 2014 May 20;14:347
pubmed: 24885354
FASEB J. 2020 Jun;34(6):7733-7744
pubmed: 32277856
Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4743-52
pubmed: 19407006
Nat Rev Rheumatol. 2021 Aug;17(8):475-486
pubmed: 34188206
Lung. 1998;176(4):267-80
pubmed: 9617743
J Autoimmun. 2012 Aug;39(1-2):9-14
pubmed: 22209352
J Autoimmun. 2012 Sep;39(3):161-7
pubmed: 22749831
FASEB J. 2014 Jul;28(7):3090-102
pubmed: 24692596
Am J Physiol Cell Physiol. 2008 Nov;295(5):C1191-201
pubmed: 18768927
Am J Physiol Cell Physiol. 2012 May 1;302(9):C1331-45
pubmed: 22237406
Scand J Rheumatol Suppl. 2002;116:3-13
pubmed: 12109541
Trends Neurosci. 2011 Nov;34(11):599-609
pubmed: 21963090
Immunology. 2018 Oct;155(2):225-237
pubmed: 29750331
Front Immunol. 2021 Sep 01;12:721453
pubmed: 34539657
J Dent Res. 1987 Feb;66(2):576-82
pubmed: 3476573
Rheumatology (Oxford). 2019 Jul 1;58(7):1285-1292
pubmed: 30877775
J Periodontol. 2008 Aug;79(8 Suppl):1520-6
pubmed: 18673006
Annu Rev Pathol. 2008;3:279-312
pubmed: 18233953
Prostaglandins Leukot Essent Fatty Acids. 2018 Nov;138:81-89
pubmed: 26858146